Immunitybio Inc (IBRX) fair value: what the stock is really worth
As of Nov 10, 2026: fair value (intrinsic value) of Immunitybio Inc stock $4.12, price $6.75, that is 38.9% below the price, quality 28 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.
How to read this chart
60‑month range $1.26 – $11.80 · fair‑value band $3.09 – $5.16 · the $6.75 price screens above the $4.12 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.
Follow Immunitybio in your weekly email
Every Wednesday you see whether Immunitybio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases.
Show moreShow less
Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors.
Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology.
The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
Stock analysis
Immunitybio Inc (IBRX) currently trades at $6.75, while our estimate is $4.12, 39% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $3.09 (bear) to $5.16 (bull), the price of $6.75 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Immunitybio Inc reported revenue of $113M in FY2025 versus $934K in FY2021, a compound +231.9%/yr. Reported net income was −$351M in FY2025.
Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (medium confidence).
What moves the price
The share trades about 42% below its 52-week high and 241% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −39%, IBRX screens richer than that median.
Fair Value
Bear$3.09Fair Value $4.12Bull$5.16
Price $6.75 · Downside -38.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Quality Score breakdown
Overall quality28/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability12
How much profit the company makes from its sales and capital
Quality Growth89
Are margins and returns getting better?
Cashflow8
Do the profits arrive as real cash?
Financial strength20
Debt, balance sheet and risk of trouble
Investment68
Does it invest with discipline instead of growing at any price?
Low Volatility50
How calm the share price moves, does not count
Price momentum50
Price momentum of the last 3 to 12 months, does not count
In the last 6 months, 3 officers or directors sold shares worth $5.0M and none bought.
SaleBarry J. SimonDirector6× since Jan 20, 2026: 475,000 shares, avg. $9.28$4.4MOct 5, 202610b5-1 plan
SaleCheryl CohenDirector2× since Jul 2, 2026: 212,266 shares, avg. $9.88$2.1MOct 2, 202610b5-1 plan
SaleChristobel SeleckyDirector4× since Jan 16, 2026: 356,200 shares, avg. $8.42$3.0MJul 1, 202610b5-1 plan
Plus 4 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+668.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+184.8%
Start year 2020 (pandemic). Over 10 years: +85.4% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+54.8%
’13
’14
’15
’16
’17
’18
’19
’20
’21
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−36,509.1% (2020) → −226.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (94 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Very negative
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks
Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score28 · Bottom 25%
Fair Value upside−38.9% · Below median
Profitability
Return on equity (12 months)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−70.0% · Bottom 25%
Operating margin (12 months)−159.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)52.3% · Top 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months)38.79× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 20
VALUE 0: the price sits above our fair-value range.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Immunitybio Inc Fair Value". https://www.fairvalue-calculator.com/stock/IBRX
Frequently asked questions
Is Immunitybio Inc (IBRX) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $4.12 versus a price of $6.75, about 39% lower (overvalued).
What is the fair value of IBRX?
Our estimate for Immunitybio Inc is $4.12 (as of Nov 11, 2026), built from audited fundamentals. The current price: $6.75.
What is the quality score of IBRX?
Immunitybio Inc has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Immunitybio Inc (IBRX)?
Our calculated price target is the estimate of $4.12 (as of Nov 11, 2026). Cautious scenario $3.09, optimistic scenario $5.16. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Immunitybio Inc stock forecast for 2026?
Our estimate puts fair value at $4.12, about 39% lower versus a price of $6.75 (overvalued). Cautious scenario $3.09, optimistic scenario $5.16. The calculation is refreshed regularly with new filings.
What is the revenue of Immunitybio Inc (IBRX)?
Immunitybio Inc reported trailing-twelve-month revenue of about $183M (latest available figure, as of Nov 11, 2026).
What is the intrinsic value of Immunitybio Inc (IBRX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Immunitybio Inc it is $4.12 per share (as of Nov 11, 2026), against a price of $6.75.
Is Immunitybio Inc stock overvalued or undervalued in 2026?
As of Nov 11, 2026, IBRX trades above its calculated fair value: price $6.75, fair value $4.12, a gap of about −39% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IBRX?
No. The price is what the market pays today ($6.75); the fair value is what the company's own numbers justify ($4.12). For Immunitybio Inc the two are $2.63 per share apart. That gap is exactly why we show both numbers side by side.
How much is Immunitybio Inc worth?
The market values Immunitybio Inc at about $7.1B (market capitalisation, as of Nov 11, 2026). Per share that is $6.75; our models calculate a fair value of $4.12 per share.
What do the bullish and bearish scenarios say about IBRX?
Our models span a range for Immunitybio Inc: cautious scenario $3.09, base $4.12, optimistic $5.16 per share (as of Nov 11, 2026, price $6.75). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Immunitybio Inc (IBRX)?
Balance-sheet figures for Immunitybio Inc (as of Nov 11, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is IBRX from its 52-week high?
Immunitybio Inc trades at $6.75, about 42% below its 52-week high of $11.55 and 241% above the low of $1.98 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $4.12 is for.
Which stocks are comparable to Immunitybio Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Immunitybio Inc stock attractive at the current price?
The data as of Nov 11, 2026: price $6.75, calculated fair value $4.12 (−39%), Quality Score 28/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Immunitybio Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Immunitybio Inc (IBRX)?
The closing price on Nov 10, 2026 was $6.75. Our estimate is $4.12, about 39% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Immunitybio Inc right now?
The price sits above even our optimistic bull case ($5.16). The favourable scenario is already priced in. Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Immunitybio Inc
How large is the market capitalisation of Immunitybio Inc (IBRX)?
The market capitalisation of Immunitybio Inc is $7.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Immunitybio Inc (IBRX)?
The price-to-sales ratio of Immunitybio Inc is 41.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Immunitybio Inc (IBRX)?
Earnings per share at Immunitybio Inc are $−1.06. Earnings per share over the last twelve months: total profit spread across every single share.
What is the EBIT return on assets of Immunitybio Inc (IBRX)?
On an EBIT basis the return on assets of Immunitybio Inc is −76.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Immunitybio Inc (IBRX)?
The operating margin of Immunitybio Inc is −160% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Immunitybio Inc (IBRX)?
Revenue at Immunitybio Inc is growing +52.3% versus a year earlier (3y avg +679%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Immunitybio Inc (IBRX) generate?
The free cash flow of Immunitybio Inc is −$309M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Immunitybio Inc (IBRX) carry?
The net debt of Immunitybio Inc is $790M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Immunitybio Inc in the live analysis
One click puts Immunitybio Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 11, 2026
